So, talking money, a reasonable portion of my portfolio is in Synairgen. www.synairgen.com/
They were developing a nebulised Interferon B to deal with COPD, when along came COVID. Their product, SNG001 and variants, seems to have passed various Phase II studies, the big one being the ACTIV2 one in the States. Everything I read about them seems really positive.
This brings with it the stuff that is missing from these little research companies, which are full of boffins with no marketing, licensing, regulatory, large scale manufacturing etc skills - some financial backing but more importantly assistance scaling up manufacturing and overall governmental support. Word is that some of the large companies are sniffing around these little ones but are reluctant to jump until approvals are gained, which makes sense.
Anyway, I'm sure these kinds of products will be beneficial alongside the vaccines.
|